Literature DB >> 1479052

Acute and chronic administration of trazodone in the treatment of disruptive behavior disorders in children.

J K Zubieta1, N E Alessi.   

Abstract

We report the results of an open trial of trazodone in the treatment of severe behavioral disturbances in a sample of 22 hospitalized children previously found to be unresponsive to other treatments. Response to treatment was assessed by overall clinical criteria and improvements in individual symptom dimensions during the inpatient hospitalization. Thirteen children (67%) were found to benefit from the introduction of trazodone. Aggressive, impulsive behaviors were symptoms most frequently improved by this agent. Three of those found to be nonresponders actually worsened in symptomatology. A follow-up interview of the parents was conducted 3-14 months after discharge from the inpatient unit, for those children who initially responded to trazodone administration. The results of this interview suggest that the effect of trazodone was persistent for a prolonged period of time after the initial inpatient trial. Trazodone appears to be of value in the management of severe behavioral disturbances in children. The possible mechanism of action of trazodone is discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1479052

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  8 in total

1.  Treatment Options for the Cardinal Symptoms of Disruptive Mood Dysregulation Disorder.

Authors:  Leon Tourian; Amélie LeBoeuf; Jean-Jacques Breton; David Cohen; Martin Gignac; Réal Labelle; Jean-Marc Guile; Johanne Renaud
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2015-03-04

Review 2.  Pharmacological aspects of the treatment of conduct disorder in children and adolescents.

Authors:  Oleg V Tcheremissine; Lori M Lieving
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 3.  Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents.

Authors:  Jonathan Ipser; Dan J Stein
Journal:  Psychopharmacology (Berl)       Date:  2006-09-16       Impact factor: 4.530

4.  The sedating antidepressant trazodone impairs sleep-dependent cortical plasticity.

Authors:  Sara J Aton; Julie Seibt; Michelle C Dumoulin; Tammi Coleman; Mia Shiraishi; Marcos G Frank
Journal:  PLoS One       Date:  2009-07-01       Impact factor: 3.240

5.  Clinic-based retrospective analysis of psychopharmacology for behavior in fragile x syndrome.

Authors:  Elizabeth Berry-Kravis; Allison Sumis; Crystal Hervey; Shaguna Mathur
Journal:  Int J Pediatr       Date:  2012-07-30

6.  Treating persistent adolescent aggression.

Authors:  John Peterson; Christopher Sheldon
Journal:  Curr Treat Options Neurol       Date:  2006-09       Impact factor: 3.972

7.  Imaging the neural circuitry and chemical control of aggressive motivation.

Authors:  Craig F Ferris; Tara Stolberg; Praveen Kulkarni; Murali Murugavel; Robert Blanchard; D Caroline Blanchard; Marcelo Febo; Mathew Brevard; Neal G Simon
Journal:  BMC Neurosci       Date:  2008-11-13       Impact factor: 3.288

8.  Neural Responses to Fluoxetine in Youths with Disruptive Behavior and Trauma Exposure: A Pilot Study.

Authors:  Soonjo Hwang; Unsun Chung; Yongmin Chang; Eunji Kim; Ji-Woo Suk; Harma Meffert; Christopher Kratochvil; Ellen Leibenluft; James Blair
Journal:  J Child Adolesc Psychopharmacol       Date:  2021-06-01       Impact factor: 2.576

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.